The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Subscribe To Our Newsletter & Stay Updated